Industry Deep Dive

HealthTech & BioTech

The most regulated sector deserves the most prepared legal team.

HealthTech and BioTech companies face the highest regulatory stakes in startup law. A HIPAA violation doesn't just mean a fine — it can end your company's ability to operate. FDA regulatory missteps can delay market entry by years. And in a sector where clinical data is both the core asset and the greatest liability, legal infrastructure isn't optional — it's existential.

HIPAA
Compliant by design
FDA
Pathway navigation
BAA
Framework expertise

Key Legal Risks

The most common legal vulnerabilities for HealthTech & BioTech companies — and why they compound fast.

1

HIPAA violations from improperly designed data architectures or missing Business Associate Agreements

2

FDA regulatory strategy failures that misclassify medical software or devices

3

Clinical data ownership disputes in research partnerships with hospitals and academic institutions

4

Biotech IP protection gaps leaving core research innovations exposed

5

Missing informed consent frameworks for health data collection and use

6

International health data transfer violations (EU GDPR has heightened requirements for health data)

Who We Work With

The typical HealthTech & BioTech company that engages Lexium.

Digital health apps, clinical decision support tools, biotech research companies, medical device startups, pharmaceutical platforms, and health data analytics businesses.

The Lexium Edge

We combine regulatory depth with startup speed. Our health frameworks are HIPAA-compliant by design, FDA-pathway aware, and built to survive life science investor due diligence scrutiny.

Legal Services by Priority

The services HealthTech & BioTech companies need most — ranked by urgency and impact.

Critical priority

Data Privacy & Compliance

View service

HIPAA applies to any entity handling protected health information. Beyond HIPAA, health data triggers the highest protections under GDPR and most state privacy laws. A single misconfigured BAA can result in OCR investigation.

Critical priority

Intellectual Property Protection

View service

Biotech IP — patents for compounds, processes, diagnostic methods — requires early, strategic filing. University research partnerships add complexity around IP ownership that must be resolved in advance.

High priority

Contracts & Commercial Agreements

View service

Business Associate Agreements, clinical study agreements, hospital data sharing contracts, and research collaboration agreements all require specialized drafting that standard templates cannot provide.

High priority

Fundraising & Investment Readiness

View service

Life science investors conduct the most intensive legal due diligence in venture — covering IP chain of title, regulatory status, clinical data rights, and HIPAA compliance before investment.

Medium priority

Company Formation & Structure

View service

Biotech companies often need specialized structures for managing university license agreements, research subsidiaries, and clinical stage development with strategic partners.

HealthTech & BioTech Legal FAQ

The questions HealthTech & BioTech founders and operators ask us most — answered directly.

Ready to build your HealthTech & BioTech legal foundation?

Let's map your exact legal needs — no obligation, no jargon. Just a direct conversation about where you are and what you need.